RareMed Solutions, a provider of patient support services for complex therapies, on Tuesday announced an expansion of its relationship with biopharmaceutical company PTC Therapeutics with the launch of non-commercial pharmacy dispensing services for PTC's therapy, Sephience (sepiapterin).

The US Food and Drug Administration (FDA) recently approved Sephience for the treatment of phenylketonuria (PKU) in both adult and paediatric patients.

RareMed will be providing non-commercial pharmacy dispensing services to support patients in challenging circumstances. These services are designed to provide both patients and healthcare providers with appropriate assistance.

To provide seamless access and support, RareMed's RareSupport Team is expanding. According to the company, a larger team of liaisons will play a crucial role in providing outreach and coordination efforts across PTC's supported therapies so that every patient may receive appropriate, personalised care and attention, while leadership will provide guidance, oversight, and compliance support. By expanding the team, RareMed aims to facilitate a smoother, more coordinated experience for all stakeholders involved in the treatment process.